DOCSLIB.ORG

Lapdap: a New Antimalarial for Africa

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lapdap: a New Antimalarial for Africa No. 70 October 2003 TDR UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) CONTENTS 2 Lapdap: a new antimalarial for Africa 3 FIND: finding new diagnostics 4 SWG identifies focused research agenda for malaria 5 FAME: an initiative to promote medical research publishing in Africa 6 HINARI approaches major milestone 8 Partnership for Social Science in Malaria Control: five-year strategy envisages centres of excellence in Africa 9 Ethical, legal and social issues of genetically modified disease vectors in public health 10 TDR’s Co-artemether Product Development Team: a public-private partnership in action 12 WHO-Aventis Collaborative Working Group: one cornerstone of a global alliance for controlling and eliminating African sleeping sickness 13 Miltefosine: what next? 14 TDR meets the tropical disease research community in Germany 15 TDR trainee profile 16 New research awards 22 Publications WHO/TDR/Crump 24 Deadlines KEYNOTE ARTICLE Lapdap: a new antimalarial for Africa | page 2 | www.who.int/tdr KEYNOTE ARTICLE Lapdap: a new antimalarial for Africa CONTACT For children more than three months of age, half a Lapdap tablet is ground to powder on a Dr Tom Kanyok spoon and mixed with water. TDR/PRD Tel: (+41 22) 791 3684 Fax: (+41 22) 791 4954 A new antimalarial treatment, a E-mail: [email protected] combination of chlorproguanil and dapsone known as ‘Lapdap’ which was developed by TDR and partners,1 has been approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treat- ment of uncomplicated Plasmodium falciparum, the most WHO/TDR/Crump life-threatening malaria parasite, in adults and children more than three months of age. Lapdap is effective against drug-resistant para- 1 Partners involved in the sites and is anticipated to be available in several African countries development of Lapdap: by the end of 2003, assuming that national approval is granted. • TDR • University of Liverpool • Liverpool School of Tropical Affordable new antimalarials are badly needed in sub-Saharan Africa, Medicine TDRnews where first-line treatments (e.g. chloroquine, sulphadoxine/pyri- • London School of Tropical methamine) are failing due to increasing parasite resistance. Lapdap Medicine and Hygiene is published three times a year by • GlaxoSmithKline the UNDP/World Bank/WHO Special is cheap to produce and has a short half-life, presenting a smaller • UK Department for Programme for Research and ‘window’ for selection of resistance than drugs with a longer half-life, International Development Training in Tropical Diseases (TDR). so the antimalarial efficacy should be retained for longer. • Falade CO, Malaria Research Full article text available Laboratories, College of on the TDR website. Medicine, University of Ibadan, All material submitted to TDRnews The safety and effectiveness of Lapdap will now be further assessed Ibadan, Nigeria undergoes editorial review. through surveillance of phase IV trials; so far, in the phase III clinical • Kremsner PG, Medical Research Articles and illustrations published Unit, Albert Schweitzer in TDRnews which are not programme in sub-Saharan Africa, the most common adverse effect Hospital, Lambaréné, Gabon copyrighted may be reproduced, was anaemia, which occurred in only a small proportion of patients • Kublin JG, The Malawi- provided credit is given to TDR and was of limited duration.The safety of Lapdap will also be assessed Liverpool-Wellcome Trust and provided such reproduction is Programme for Tropical not used for commercial purposes. in specific patient groups, e.g. very young children, pregnant women, Medicine Research, PO Box Articles do not necessarily those co-infected with HIV, those with a predisposition to certain 30096 Chichiri, Blantyre, reflect the views of WHO. kinds of anaemia. Since chlorproguanil-dapsone is pharmacologically Malawi (P Chimpeni, J Kublin, C Mkandala) Editor Nina Mattock similar to sulphadoxine/pyrimethamine, further work is also needed • Premji Z, Muhimbili Medical Production team to understand how the useful therapeutic life of chlorproguanil- Center, Dar es Salaam, Tanzania • Winstanley PA, the Kenya- Jocelyne Bruyère, dapsone will be affected by the growing resistance to S/P. Liverpool Wellcome Trust Andy Crump, Jens Kastberg Programme for Tropical Design Lisa Schwarb To what extent chlorproguanil-dapsone will, by itself, find use in the Medicine Research, Kilifi, Layout Nanette Vabø treatment of malaria is, however, uncertain.WHO strategy is to use Kenya; and the Department of Pharmacology and new antimalarial drugs in combination with an artemisinin derivative, Therapeutics, University of Tel. (+41) 22 791 3725 and Lapdap has the potential to be used in this way as a ‘loose’ Liverpool, Liverpool L69 3GE, UK Fax (+41) 22 791 4854 combination with an artemisinin.The development of a fixed-dose • Wellcome Trust E-mail [email protected] combination of Lapdap with artesunate (chlorproguanil-dapsone- 2 Partners in discussion for the Web www.who.int/tdr artesunate or CDA) is already under way and is currently undergoing development of chlorpro- Address TDR phase II clinical trials in Malawi.The creation of a public-private part- guanil-dapsone-artesunate: World Health Organization • TDR Avenue Appia 20 · 1211 Geneva 27 nership to further develop this combination drug is at an advanced • GlaxoSmithKline Switzerland stage of negotiation.2 • Medicines for Malaria Venture 2 • TDRnews • No 70 • OCT 2003 DIAGNOSTICS RESEARCH FIND: finding new diagnostics An independent non-profit foundation based in activities rather than through open requests for CONTACT Geneva and known as the Foundation for investigator-initiated proposals. However, some Innovative New Diagnostics (FIND)1 was launched investigator-initiated proposals will be funded Dr Mark Perkins in May 2003 by TDR and the Bill and Melinda each year, and two joint FIND/TDR requests for Gates Foundation. applications have already been issued, calling for Manager, Diagnostics research towards 1) an antigen detection system Product Research and FIND represents an expansion of TDR’s ongoing for case-finding or follow-up, and 2) improved Development, TDR efforts to find and develop new diagnostics for sputum microscopy (this being the most widely Tel: (+41) 22 791 4141 neglected infectious diseases; in particular it builds available diagnostic test for tuberculosis, which on the former TDR Tuberculosis Diagnostics has been in use for more than 100 years). Fax: (+41) 22 791 4854 Initiative (TBDI).With funding from the Gates E-mail: [email protected] Foundation (US$30 million for the first five years), FIND will be directed by Giorgio Roscigno, the FIND will be able to quickly turn methods into founding director of the Global Alliance for TB products, untested products into evaluated Drug Development, while TDR’s own Mark products, and promising tests into tools with Perkins will become FIND’s scientific director. demonstrated impact and feasibility. The FIND offices are located next door to TDR’s new premises (see page 11). Tuberculosis (TB) was chosen as the first target for FIND because of the magnitude of the TB “The recent outbreak of SARS illustrates the problem (TB kills one person every 15 seconds) need for easy-to-use and accurate diagnostics and because, once detected, cases can be ably to aid in the control of tropical diseases” says treated by existing health systems. Ultimately TDR director Carlos Morel.“Great strides have however, other neglected diseases will be the been made in developing drugs and increasing focus of attention. patient access to good medicines, but diagnosis remains a stumbling block in public health. Public FIND and TDR have a jointly elaborated work- health needs can only be met by partnerships at plan on TB diagnostics, which will be carried out all levels”. through managing a portfolio of focused research Can sputum microscopy be improved? It has been in use for more than 100 years and is the most widely available diagnostic test for TB. 1 www.finddiagnostics.org/ WHO/TDR/Crump TDRnews • No 70 • OCT 2003 • 3 SCIENTIFIC WORKING GROUP Scientific Working Group CONTACT identifies focused research Dr Yeya Touré Manager, Molecular agenda for malaria Entomology Committee, and Malaria Research Coordinator, TDR Intermittent preventive Tel: (+41) 22 791 3884/4453 therapy for malaria: Fax: (+41) 22 791 4854 this woman will receive sulphadoxine/pyri- E-mail: [email protected] methamine tablets to combat possible malaria infection during her pregnancy. WHO/TDR/Crump The Scientific Working Group (SWG) is one of • Evaluation of artemisinin-based combination the major tools for TDR, for bringing the disease therapies. emphasis back into the Programme.An SWG • Development of new drugs with novel targets. meeting takes place once every five years for each • New approaches to drug-based malaria disease. It sets the research agenda not only for prevention including intermittent preventive TDR but for the whole of the disease field, from therapy in children and during pregnancy. basic science to policy-making. Experts from all • Strategies for scaling up the use of geographic areas, including disease endemic insecticide-treated nets. countries, take part in the meetings, which are • Genomics for discovery and development of five-day exercises. drugs, diagnostics, vaccines, insecticides, and anti-parasite effector molecules. The focus of the SWG meeting held in March • Strategic and basic research in vector-parasite- 2003 was malaria, which remains a major threat
Load more

Recommended publications
  • Trypanocidal Activity of Ethanolic Leaf Extract of Andrographis Paniculata
    Science World Journal Vol. 15(No 4) 2020 www.scienceworldjournal.org ISSN: 1597-6343 (Online), ISSN: 2756-391X (Print) Published by Faculty of Science, Kaduna State University TRYPANOCIDAL ACTIVITY OF ETHANOLIC LEAF EXTRACT OF ANDROGRAPHIS PANICULATA 1* 2 3 4 Ladan Z., Olanrewaju T. O., Maikaje D.B., and Waziri P. N. Full Length Research Article 1Department of Chemistry, Kaduna State University, Kaduna, Nigeria 2Human African Trypanosomiasis Research Department, Nigerian Institute for Trypanosomiasis Research, Kaduna, Nigeria 3Department of Microbiology, Kaduna State University, Kaduna, Nigeria 4Department of Biochemistry, Kaduna State University, Kaduna, Nigeria *Corresponding Author’s Email Address: [email protected] Phone: 2347030475898 ABSTRACT animal Trypanosomiasis (Achenef and Bekele, 2013; Giordani et Andrographis paniculata used in this study belongs to Acanthacae al., 2016). Various industries are now on the search for sources of family and is commonly known as king of bitters. This study aimed alternative which include synthetic and natural products. Medicinal at evaluating effect of A. paniculata leaf extract on experimental plants remain a major source of alternative medicine and scientific rats infected with Trypanosoma brucei brucei. Cold maceration was investigations have shown that various plants indicate promising used for extraction and the biomass was fractionated in open results for the development of cheaper less toxic drugs for column chromatography. One of the ethanolic fractions obtained treatment and management of trypanosomiasis (Simoben et al., from A. paniculata was evaluated for in vitro and in vivo activities 2018). Andrographis paniculata evaluated in this study belong to using RPMI 1640 cell culture media and experimental wistar rats Acanthacae family of the plant kingdom and commonly known as respectively.
    [Show full text]
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • Of!Transcription!In!The!African! Trypanosome!Trypanosoma*Brucei.!
    ! ! ! ! ! ! Epigenetic!control!of!transcription!in!the!African! Trypanosome!Trypanosoma*brucei.! ! ! ! ! ! by! Louise!Elizabeth!Kerry! ! ! ! ! ! Thesis!submitted!in!partial!fulfillment!of!the!requirements!for!the!degree!of! Doctor!of!Philosophy!(Ph.!D.)!in!Molecular!and!Cellular!Biosciences.! Department!of!Life!Sciences,!Division!of!Cell!and!Molecular!Biology,! Imperial!College!London! ! ! ! ! ! ! Declaration!! ! Declaration!of!originality! I! declare! that! all! of! the! work! presented! in! this! thesis! is! my! own,! and! that! all! else,! information,! data,! results,! figures! and! ideas! from! another! source! or! from! collaborations! have!been!appropriately!referenced!or!acknowledged.! ! ! ! Louise!Elizabeth!Kerry!! November!2017! ! ! Copyright!declaration! The! copyright! of! this! thesis! rests! with! the! author! and! is! made! available! under! a! Creative! Commons!Attribution!NonOCommercial!No!Derivatives!license.!Researches!are!free!to!copy,! distribute!or!transmit!the!thesis!on!the!condition!that!they!attribute!it,!that!they!do!not!use! it!for!commercial!purposes!and!that!they!do!not!alter,!transform!or!build!upon!it.!!For!any! reuse! or! redistribution,! researchers! must! make! clear! to! others! the! license! terms! of! this! work.! ! ! ! ! ! ! 1! Abstract! Abstract! ! Trypanosoma! brucei! relies! on! an! essential! Variant! Surface! Glycoprotein! (VSG)! coat! for! survival!in!the!mammalian!bloodstream.!A!single!VSG!gene!is!transcribed!by!RNA!polymerase!I!(Pol!I)! in! a! strictly! monoallelic! fashion! from! one! of!
    [Show full text]
  • Annual Review 2004 Contents Contentsforeword
    Annual Review 2004 Contents ContentsForeword ........................................................................................................................... 3 Editor’s Note ..................................................................................................................... 4 Organization Chart ............................................................................................................ 5 Administrative Board .......................................................................................................... 6 Special Events..................................................................................................................... 8 Consultants ...................................................................................................................... 13 Visiting Professors ............................................................................................................ 13 Faculty Board ...................................................................................................................13 Faculty Senate ..................................................................................................................14 Department of Clinical Tropical Medicine ........................................................................ 15 Department of Helminthology ......................................................................................... 22 Department of Medical Entomology ...............................................................................
    [Show full text]
  • Genomics and Expected Benefits for Vector Entomology
    4 Genomics and expected benefits for vector entomology Christos Louis# Abstract This paper summarizes the gains expected for vector entomology from the acquisition of the genome sequence of disease-transmitting arthropods. The results of this kind of high-throughput science, especially the direct consequences that could be summarily described as post-genomic activities, may lead to a better understanding of the biology of the vectors, including population studies, interactions with the disease agents and, finally, the direct development of tools, biological or bioinformatics- based, to be used in their control. Keywords: genome sequencing; genome mining; comparative genomics The facts and the prospects Although the etymology of the term genomics is obvious, in contrast, its definition is fairly vague. Interestingly, unless one would encompass in it the notion of ‘high- throughput research’, Bridges’ pioneering work on the cytogenetic mapping using the polytene chromosomes of Drosophila (Bridges 1935) would definitely qualify as genomic research, possibly marking the beginning of the discipline. The particularly tedious and time-consuming closing of gaps in the whole genome sequence (WGS) of the same organism, on the other hand, can hardly be described as ‘high throughput’, thus its inclusion in the category of ‘-ics’ science could theoretically merely be done as a typical example of ‘post-genomics’. In spite of these philological considerations genomics has not only found its place in biological research, even more so, it represents a constantly expanding field, also due to the continual development of new biotechnological, technological and informatics-based tools. The first reported completion of the sequence of a large segment of eukaryotic DNA, that of chromosome XI of Saccharomyces cerevisiae (Dujon et al.
    [Show full text]
  • Artemether-Lumefantrine (Six-Dose Regimen) for Treating Uncomplicated Falciparum Malaria (Review)
    Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria (Review) Omari AAA, Gamble CL, Garner P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2009, Issue 1 http://www.thecochranelibrary.com Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 5 DISCUSSION ..................................... 9 AUTHORS’CONCLUSIONS . 9 ACKNOWLEDGEMENTS . 10 REFERENCES ..................................... 10 CHARACTERISTICSOFSTUDIES . 13 DATAANDANALYSES. 20 Analysis 1.1. Comparison 1 Artemether-lumefantrine vs amodiaquine, Outcome 1 Total failure by day 28. 22 Analysis 1.2. Comparison 1 Artemether-lumefantrine vs amodiaquine, Outcome 2 Total failure by day 14. 23 Analysis 1.3. Comparison 1 Artemether-lumefantrine vs amodiaquine, Outcome 3 Gametocyte carriage on day 14. 23 Analysis 2.1. Comparison 2 Artemether-lumefantrine vs chloroquine plus sulfadoxine-pyrimethamine, Outcome 1 Total failurebyday28. ................................ 24 Analysis 2.2. Comparison 2 Artemether-lumefantrine
    [Show full text]
  • Drugs and Drug Resistance in African Animal Trypanosomosis: a Review
    European Journal of Applied Sciences 5 (3): 84-91, 2013 ISSN 2079-2077 © IDOSI Publications, 2013 DOI: 10.5829/idosi.ejas.2013.5.3.75164 Drugs and Drug Resistance in African Animal Trypanosomosis: A Review Achenef Melaku and Bekele Birasa Department of Veterinary Pharmacy and Biomedical Sciences, Faculty of Veterinary Medicine, University of Gondar, Ethiopia Abstract: Trypanosomosis is the most serious animal health problem in sub-Saharan Africa and prevents the keeping of animals over millions square kilometres of potentially productive land. Trypanocidal drugs belonging to different chemical families and they are used quite intensively in veterinary medicine. Drug for control of animal trypanosomosis relies essentially on three drugs namely homidium salts, diminazene aciturate and isometamidium chloride. About thirty five million doses of trypanocidal drugs are used annually in the treatment of animal trypanosomosis in Africa. Most of these drugs are very old and utilized for a long period of time. Hence, treatment of trypanosomosis is complicated by development of drug resistance. Drug resistance has been reported in 17 countries of Africa. The exact mechanism how trypanosomal parasite develop resistant and the factors responsible for the development of drug resistance are yet to establish. In addition, it is very unlikely that new trypanocidal drugs will be released into the market in the near future. Therefore, it is essential to maintain the efficacy of the currently available drugs through proper utilization. The general features of trypanosomosis, drugs for the treatment and drug resistance in African trypanosomoses are briefly reviewed in this paper and measures to combat drug resistance especially at field level are also suggested.
    [Show full text]
  • Review of T-2307, an Investigational Agent That Causes Collapse of Fungal Mitochondrial Membrane Potential
    Journal of Fungi Review Review of T-2307, an Investigational Agent That Causes Collapse of Fungal Mitochondrial Membrane Potential Nathan P. Wiederhold Fungus Testing Laboratory,Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, San Antonio, TX 78229, USA; [email protected] Abstract: Invasive infections caused by Candida that are resistant to clinically available antifungals are of increasing concern. Increasing rates of fluconazole resistance in non-albicans Candida species have been documented in multiple countries on several continents. This situation has been further exacerbated over the last several years by Candida auris, as isolates of this emerging pathogen that are often resistant to multiple antifungals. T-2307 is an aromatic diamidine currently in development for the treatment of invasive fungal infections. This agent has been shown to selectively cause the collapse of the mitochondrial membrane potential in yeasts when compared to mammalian cells. In vitro activity has been demonstrated against Candida species, including C. albicans, C. glabrata, and C. auris strains, which are resistant to azole and echinocandin antifungals. Activity has also been reported against Cryptococcus species, and this has translated into in vivo efficacy in experimental models of invasive candidiasis and cryptococcosis. However, little is known regarding the clinical efficacy and safety of this agent, as published data from studies involving humans are not currently available. Keywords: T-2307; aromatic diamidine; in vitro susceptibility; mitochondrial membrane; mitochondrial membrane potential; Candida; Cryptococcus Citation: Wiederhold, N.P. Review of T-2307, an Investigational Agent That Causes Collapse of Fungal Mitochondrial 1. Introduction Membrane Potential. J. Fungi 2021, 7, 130.
    [Show full text]
  • How to Protect Yourself Against Malaria 1 Fig
    From our Whitepaper Files: How to > See companion document Protect Yourself Against Malaria World Malaria Risk Chart 2015 Edition Canada 67 Mowat Avenue, Suite 036 Toronto, Ontario M6K 3E3 (416) 652-0137 USA 1623 Military Road, #279 Niagara Falls, New York 14304-1745 (716) 754-4883 New Zealand 206 Papanui Road Christchurch 5 www.iamat.org | [email protected] | Twitter @IAMAT_Travel | Facebook IAMATHealth THE ENEMY area. Of the 460 Anopheles species, approximately 100 can transmit malaria Sunset — the hunt for human blood begins. parasites. From dusk to dawn the female Anopheles, Mosquitoes prey on a variety of hosts — the malaria-carrying mosquito searches for a host humans, monkeys, lizards, birds — carrying to supply her with blood. Blood is an absolute different species of malaria parasites which in necessity for her because it provides the protein turn infect only specific hosts. Of the approxi- needed for the development of her eggs which mately 50 different species of malaria parasites she later deposits in her breeding place. sharing the genetic name Plasmodium, only She has a tiny, elegant body, measuring 5 infect humans: Plasmodium falciparum, from 8 mm to 1 cm. She has dark spots on the killer; Plasmodium vivax; Plasmodium ovale, her wings, three pairs of long, slender legs and Plasmodium malariae and Plasmodium knowlesi. a prominent tubular proboscis with which The latter, a malaria parasite of Old World she draws blood. monkeys, has been identified to infect humans Fig. 1 Female Anopheles mosquito. The Anopheles enters your room at night. in Southeast Asia. In the past this parasite has Image source: World Health Organization You may recognize her by the way she rests been misdiagnosed as Plasmodium malariae.
    [Show full text]
  • Hydroxychloroquine Or Chloroquine for Treating Coronavirus Disease 2019 (COVID-19) – a PROTOCOL for a Systematic Review of Individual Participant Data
    Hydroxychloroquine or Chloroquine for treating Coronavirus Disease 2019 (COVID-19) – a PROTOCOL for a systematic review of Individual Participant Data Authors Fontes LE, Riera R, Miranda E, Oke J, Heneghan CJ, Aronson JK, Pacheco RL, Martimbianco ALC, Nunan D BACKGROUND In the face of the pandemic of SARS CoV2, urgent research is needed to test potential therapeutic agents against the disease. Reliable research shall inform clinical decision makers. Currently, there are several studies testing the efficacy and safety profiles of different pharmacological interventions. Among these drugs, we can cite antimalarial, antivirals, biological drugs, interferon, etc. As of 6 April 2020 there are three published reportsand 100 ongoing trials testing hydroxychloroquine/chloroquine alone or in association with other drugs for COVID-19. This prospective systematic review with Individual Participant data aims to assess the rigour of the best-available evidence for hydroxychloroquine or chloroquine as treatment for COVID-19 infection. The PICO framework is: P: adults with COVID-19 infection I: chloroquine or hydroxychloroquine (alone or in association) C: placebo, other active treatments, usual standard care without antimalarials O: efficacy and safety outcomes OBJECTIVES To assess the effects (benefits and harms) of chloroquine or hydroxychloroquine for the treatment of COVID-19 infection. METHODS Criteria for considering studies for this review Types of studies We shall include randomized controlled trials (RCTs) with a parallel design. We intend to include even small trials (<50 participants), facing the urgent need for evidence to respond to the current pandemic. Quasi-randomized, non-randomized, or observational studies will be excluded due to a higher risk of confounding and selection bias (1).
    [Show full text]
  • The Molecular Biology of Insect Disease Vectors
    THE MOLECULAR BIOLOGY OF INSECT DISEASE VECTORS JOIN US ON THE INTERNET VIA WWW, GOPHER, FTP OR EMAIL: WWW: http://www.thomson.com GOPHER: gopher.thomson.com A service of ICDP® FTP: ftp.thomson.com EMAIL: [email protected] THE MOLECULAR BIOLOGY OF INSECT DISEASE VECTORS A METHODS MANUAL Edited by J.M. CRAMPTON Division of Molecular Biology and Immunology, Liverpool School of Tropical Medicine, UK C.B. BEARD Centers for Disease Control and Prevention, Atlanta, USA and C. LOUIS Department of Biology, University of Crete m CHAPMAN & HALL London· Weinheim . New York· Tokyo· Melbourne· Madras Published by Chapman & Ball, 2-6 Boundary Row, London SEt 8HN, UK Chapman & Hall, 2-6 Boundary Row, London SEI 8HN, UK Chapman & Hall GmbH, Pappelallee 3, 69469 Weinheim, Gennany Chapman & Hall USA, 115 Fifth Avenue, New York. NY 10003. USA Chapman & Hall Japan, ITP-Japan, Kyowa Building, 3F. 2-2-1 Hirakawacho, Chiyoda-ku, Tokyo 102, Japan Chapman & Hall Australia, 102 Dodds Street, South Melbourne. Victoria 3205. Australia Chapman & Hall India, R. Seshadri, 32 Second Main Road. CIT East. Madras 600 035. India First edition 1997 © 1997 Chapman & Hall Softcover reprint of the hardcover I st edition 1997 Typeset by Saxon Graphics Ltd .• Derby ISBN-13: 978-94-010-7185-7 e-ISBN-13: 978-94-009-1535-0 DOl: 10.1007/978-94-009-1535-0 Apart from any fair dealing for the purposes of research or private study. or criticism or review. as permitted under the UK Copyright Designs and Patents Act. 1988. this publication may not be reproduced. stored, or transmitted, in any form or by any means, without the prior permission in writing of the publishers, or in the case of reprographic reproduction only in accordance with the terms of the licences issued by the Copyright Licensing Agency in the UK.
    [Show full text]
  • WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/337 (2006.01) A61K 31/48 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/395 (2006.01) A61K 31/51 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/4174 (2006.01) A61K 31/549 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/428 (2006.01) A61K 31/663 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (21) International Application Number: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, PCT/IB20 12/002768 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (22) International Filing Date: NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, 25 October 2012 (25.10.2012) RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (25) Filing Language: English ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/552,922 28 October 201 1 (28.
    [Show full text]